Media coverage about Crispr Therapeutics (NASDAQ:CRSP) has been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Crispr Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.3911457911834 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Crispr Therapeutics (CRSP) Upgraded at Zacks Investment Research (americanbankingnews.com)
- CRISPR Therapeutics AG (CRSP) performed 36.12% – Monthly upward Move – The Stocks News (press release) (thestocksnews.com)
- CRISPR Therapeutics AG (CRSP) – Focus on Unusual Volume Activity – Wall Street Morning (wallstreetmorning.com)
- Active Stock Evaluation – CRISPR Therapeutics AG (NASDAQ: CRSP) – Alpha Beta Stock (alphabetastock.com)
- Record Revenue Growth & Imminent Nasdaq Listing Could Spell Big Upside for Unknown Orgenesis (ORGS) (finance.yahoo.com)
Shares of Crispr Therapeutics (NASDAQ CRSP) traded down $1.65 on Wednesday, hitting $54.86. The company’s stock had a trading volume of 587,149 shares, compared to its average volume of 1,092,588. Crispr Therapeutics has a 12 month low of $13.50 and a 12 month high of $61.24. The firm has a market capitalization of $2,590.00 and a PE ratio of -35.40.
In related news, Director Kurt Von Emster sold 37,754 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $26.76, for a total value of $1,010,297.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thomas Woiwode sold 3,059 shares of the stock in a transaction that occurred on Friday, December 22nd. The stock was sold at an average price of $20.29, for a total value of $62,067.11. Following the completion of the transaction, the director now directly owns 4,959 shares of the company’s stock, valued at $100,618.11. The disclosure for this sale can be found here. Over the last three months, insiders sold 298,850 shares of company stock valued at $7,545,365. 39.98% of the stock is owned by corporate insiders.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.